Table 1.
Demographics and some clinical features of patients with chronic anal fissure with or without sentinel piles treated with botulinum toxin
| Variable | Overall (n = 249) | SP− (n = 181) | SP+ (n = 68) | p value |
|---|---|---|---|---|
| Age, years—median (range) (IQR) | 41 (19–82) | 41.0(15) | 39.5 (13) | NS (0.545Ω) |
| Sex—n (%) | ||||
| Female | 78 (31.3%) | 48 (26.5%) | 30 (44.1%) | 0.009* |
| Male | 171 (68.7%) | 133 (73.4%) | 38 (55.9%) | |
| Symptom duration, weeks —median | – | 12 | 16 | NS 0.247Ω |
| Objective healing after first BT injection—n (%) | 186 (74.7%) | 146 (80.7%) | 40 (58.8%) | < 0.001* |
| Objective healing after second BT injection—n (%) | 200 (80.3%) | 153 (84.5%) | 47 (69.1%) | 0.011* |
| Pre-treatment REALISE score—median (IQR) | 18 (6) | 18 (7) | 18 (6) |
NS 0.871† |
| Post-treatment REALISE score—median (IQR) | 6 (3) | 5 (3) | 7 (4) | < 0.001† |
| Post-treatment Q1 score | 1 (2) | 1 (2) | 2 (1) | < 0.001Ω |
| Post-treatment Q2 score | 1 (0) | 1 (0) | 1 (1) | 0.003Ω |
| Post-treatment Q3 score | 1 (0) | 1 (0) | 1 (1) | 0.002Ω |
| Post-treatment Q4 score | 1 (1) | 1 (0) | 1 (1) | 0.039Ω |
| Post-treatment Q5 score | 1 (1) | 1 (1) | 1 (1) | 0.017Ω |
| Recurrence during follow-up n = 226 (%) | 41 (18.1%) | 27 (15.7%) | 14 (25.9%) | NS 0.106¥ |
Data are presented as median (interquartile range) or number (%). p values refer to comparisons between with sentinel pile (SP+) and without sentinel pile (SP−) groups. Bold values indicate statistically significant results (p<0.05). †Wilcoxon signed-rank test, ¥Fisher’s exact test, *chi-squared test, ΩMann–Whitney U-test
BT botulinum toxin, IQR interquartile range, NS not significant